Noucor
Noucor is a privately-held, B2B pharmaceutical company headquartered near Barcelona, Spain, operating vertically integrated manufacturing of generic APIs, finished dose forms, food supplements and licensed NCEs. It serves pharmaceutical counterparties in 100+ markets via licensing, supply contracts and CDMO services.
- Company typePrivate
- Founded2021
- HeadquartersBarcelona, Spain
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Noucor does
Noucor is a privately-held B2B pharmaceutical company headquartered in Palau-solità i Plegamans near Barcelona, Spain. It was incorporated in 2021 as the platform vehicle of MCH Private Equity and a group of Family Office investors, consolidating Urquima (fine chemicals / API manufacturing), Noucor Health (finished dose forms and food supplements) and adjacent subsidiaries into NOUCOR GROUP, S.L. The company employs more than 500 people across three production centers and sells exclusively through business-to-business channels—strategic licensing, direct API/FDF supply and CDMO services—to pharmaceutical counterparties in more than 100 markets worldwide. Its commercial portfolio spans three granted New Chemical Entities (Rupatadine, Flutrimazole, Triflusal), a pipeline of three additional NCEs available for licensing (Albaconazole in Phase IIb, UR-63325 and UR-65318 in earlier development), and a broad generic portfolio covering CNS, cardiology, respiratory and urology therapeutic areas.
Noucor's revenue model is built on four B2B streams: licensing and royalties on NCEs and Value-Added Medicines, transactional supply of generic APIs, one-time licensing-style supply of finished dose forms, and professional services for contract manufacturing of oral solids, semi-solids and food supplements. Pricing is not publicly disclosed and is set through long-term strategic agreements, co-development contracts and supply deals rather than list pricing. The go-to-market motion is sales-led with channel-partner overlays: APIs are commercialized worldwide through agreements with other pharmaceutical companies, while NCEs and differentiated generics are out-licensed to partners with regional commercial reach. Customer segmentation is vertical, focused on pharmaceutical companies requiring APIs, FDFs or CDMO capacity and on distributors, pharmacies and hospitals receiving the manufactured products through those channels.
The underlying technology is a vertically integrated chemical-pharmaceutical manufacturing platform rather than a software platform. Urquima operates a 12,800 m² multi-product chemical plant with kilolab, pilot, semi-industrial and industrial units, 56 tonnes/year API capacity and 130 m³ maximum reaction volume. Noucor Health operates a 63,000 m² site with 20,000 m² of production space capable of producing 1.8 billion tablets, 650 million film-coated tablets, 470 million capsules and 200 million food supplement units annually. The platform is held together by multi-jurisdictional GMP certifications (US FDA, Japan PMDA, Korea FDA, Spain AEMPS), ISO 13485, ISO 14001, ISO 45001 and ISO 22716 compliance, an EcoVadis Silver Medal (76/100, top 15% globally in 2025) and a patent estate covering both granted NCEs and filed/pending applications on Bilastine, Apremilast, Zonisamide, Silodosin, Ivabradine, Desvenlafaxine and Pirvinium pamoate. AI/ML and software capabilities are not present in the disclosed operating model.
Noucor firmographics
Firmographics- Name
- Noucor
- Legal name
- NOUCOR GROUP, S.L.
- Website
- https://noucor.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Noucor is a privately-held, B2B pharmaceutical company headquartered near Barcelona, Spain, operating vertically integrated manufacturing of generic APIs, finished dose forms, food supplements and licensed NCEs. It serves pharmaceutical counterparties in 100+ markets via licensing, supply contracts and CDMO services.
- Ownership category
- akta.pro rank
Noucor industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule API Commercial Manufacturing (HLAGAHAB)
- akta.pro secondary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Noucor is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Noucor business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain
Revenue model
- Licensing of Innovative Products (NCEs): Long-term collaborations under strategic agreements for co-development, early/late licensing and distribution of New Chemical Entities. Products available for licensing include Albaconazole, UR-63325, UR-65318 in various development phases.
- Generic APIs Supply: Development and worldwide commercialization of Active Pharmaceutical Ingredients through agreements with other pharmaceutical companies. APIs manufactured at Urquima chemical plant under GMP standards.
- Finished Dose Forms (FDFs): Development and supply of generic pharmaceutical products including tablets, film-coated tablets, capsules for CNS, cardiology, respiratory and urology therapeutic areas.
- Contract Manufacturing: Development and manufacturing services for oral solids (tablets, film-coated tablets, capsules) and semi-solids (ointments, creams, gels) for other pharmaceutical companies. Also includes food supplements manufacturing.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Noucor product offering
Product offeringCore offering
Noucor is a vertically integrated pharmaceutical company that develops, manufactures, and licenses active pharmaceutical ingredients (APIs), finished dose forms (FDFs), and proprietary new chemical entities (NCEs) for sale and out-licensing to B2B pharmaceutical customers across more than 50 countries. The company operates two manufacturing centers in the Barcelona area—Urquima for chemical/API production and Noucor Health for finished dosage forms—and offers contract manufacturing services for pharmaceutical and food supplement products.
Product overview
Noucor is a vertically integrated B2B pharmaceutical company offering a diversified portfolio of innovative medicines (New Chemical Entities) and generic pharmaceutical products. The core offering includes three main commercial molecules (Rupatadine, Flutrimazole, Triflusal) alongside a pipeline of early-stage NCEs (Albaconazole, UR-63325, UR-65318). The company operates two manufacturing divisions: Urquima (chemical plant producing APIs with 56 tonnes/year capacity) and Noucor Health (pharmaceutical plant producing finished dose forms with 1.8B tablets/year capacity). Noucor also offers contract manufacturing services for oral solids and semi-solids, and maintains a separate food supplements manufacturing operation. All products are manufactured in-house from R&D through commercialization, with strategic therapeutic areas in Respiratory, Dermatology, CNS, Cardiology, and Urology.
Differentiator
Problem solved
Functional benefit
Products and services
- Generic Active Pharmaceutical Ingredients (APIs)
Quantifiable outcome
- Present in 100+ markets worldwide
- +3 more outcomes
Companies that use Noucor
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Noucor technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Noucor partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ACCIÓ International e-Trade ProgramminorNoucor participates in ACCIÓ's International e-Trade Program, an initiative supporting international trade and business development for Catalan companies.
Scale indicators15 records
Recent moves7 records
Expansion highlights5 records
Noucor competitors and assessment
Company assessmentDirect peers
- Suanfarma: Spanish-headquartered B2B pharmaceutical group with API manufacturing, CDMO services and licensing operations. Closest direct geographic and structural peer to Noucor, operating similar APIs, intermediates, and finished dose models from Spain.
- Chemo Group: Spanish-headquartered pharmaceutical group spanning API manufacturing, finished dose forms, and licensing across 100+ countries. Closely comparable to Noucor in geographic footprint, vertically integrated CDMO model, and B2B licensing strategy.
- Helsinn Group: Swiss privately-held pharma group focused on oncology and supportive care, with licensing, manufacturing, and global commercial partnerships. Comparable to Noucor's NCE out-licensing model and B2B distribution focus, though focused on specialty therapeutics rather than generics.
- Aurobindo Pharma: Vertically integrated global generic API and finished dosage form manufacturer with strong US/EU regulatory footprint. Directly comparable to Noucor on API-to-FDF vertical integration, generic molecule portfolio breadth, and B2B commercial model.
- Farmhispania: Spanish fine chemicals and API manufacturer serving global pharmaceutical companies. Closely comparable to Noucor's Urquima division on chemical synthesis capabilities, GMP compliance, and B2B API supply model.
- Dr. Reddy's Laboratories: Indian-headquartered vertically integrated pharma with API manufacturing, generic FDFs, and proprietary product licensing. Comparable to Noucor across API-to-FDF model, regulated-market certifications, and emerging pipeline out-licensing strategy.
- Medichem: Spanish API manufacturer and CDMO with deep expertise in generic active ingredients for global pharma partners. Comparable to Noucor's Urquima API business on technology platform, customer type, and geographic reach in regulated markets.
Broad incumbents
- Teva API: API division of Teva Pharmaceutical Industries, one of the world's largest generic API manufacturers. Comparable to Noucor on generic API portfolio breadth and global supply footprint, though materially larger and integrated with Teva's finished-dose operations.
- Esteve Pharmaceuticals: Larger Spanish private pharmaceutical company with proprietary specialty products, generics, API manufacturing, and CDMO capabilities. Comparable end-to-end pharma model but with broader branded portfolio and global commercial reach beyond Noucor's current scope.
Emerging players
- Curia (formerly AMRI): Global CDMO providing API development, manufacturing and finished dose services to pharma partners. Comparable to Noucor on contract manufacturing services and API capabilities, with overlap in oral solid dose expertise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Noucor social profiles
Digital presenceNoucor compliance and trust
Trust signalCompliance6 records
Noucor financial estimates
Financial estimateRevenue estimate
Valuation estimate
Noucor leadership team
Management profileNumber of profiles
Profiles1 record
Noucor subsidiaries and ownership
Company hierarchySubsidiaries4 records
Noucor funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Noucor M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Noucor
What does Noucor do?
Noucor is a vertically integrated pharmaceutical company that develops, manufactures, and licenses active pharmaceutical ingredients (APIs), finished dose forms (FDFs), and proprietary new chemical entities (NCEs) for sale and out-licensing to B2B pharmaceutical customers across more than 50 countries. The company operates two manufacturing centers in the Barcelona area—Urquima for chemical/API production and Noucor Health for finished dosage forms—and offers contract manufacturing services for pharmaceutical and food supplement products.
Is Noucor a public or private company?
Noucor is a private company. It is classified as private equity controlled and is currently operating.
When was Noucor founded?
Noucor was founded in 2021. It employs 101 to 250 people.
Where is Noucor based?
Noucor is headquartered in Barcelona, Spain, in the Europe region.
How does Noucor make money?
Four revenue lines are on record. Licensing of Innovative Products (NCEs) is the primary driver. The others are generic APIs Supply, finished Dose Forms (FDFs) and contract Manufacturing.
Who are Noucor's main competitors?
Direct peers on record are Suanfarma, Chemo Group, Helsinn Group, Aurobindo Pharma, Farmhispania, Dr. Reddy's Laboratories and Medichem. Broad incumbents are Teva API and Esteve Pharmaceuticals. Curia (formerly AMRI) is listed as an emerging player.
Does Noucor have an API?
No public API is recorded for Noucor.
What industry is Noucor in?
Noucor's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 325412 and its SIC code is 2834.